This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
KD3 is a potent peptide that blocks the p53-MDM2 and p53-MDMX interactions (which cancer cells use to shut down p53 tumor suppression), but KD3 cannot get inside cells on its own.
Two "angler peptide" conjugates succeeded:
- cTAT-KD3: entered via endocytosis, escaped endosomes, activated p53 at 1-12 µM across MCF7 (breast), A549 (lung), and HCT116 (colon) cancer cells
- cR10-KD3: entered via direct membrane translocation, activated p53 at just 1 µM in all three cell lines
The direct translocation pathway (cR10-KD3) was clearly superior: less toxic, more efficient delivery at lower concentrations, and less dependent on cell membrane type. The endocytic pathway (cTAT-KD3) required higher concentrations and varied more between cell lines.
This demonstrates that non-permeable peptide drug candidates can be rescued by conjugation to cell-penetrating peptides, expanding the pool of usable anticancer peptides.
Why it matters
The p53 pathway is disrupted in most cancers. Peptides that block p53-MDM2 interactions are potent in the test tube but useless if they cannot get inside cells. The angler peptide strategy solves this delivery problem and could be applied to many other non-permeable anticancer peptides.
The numbers in context
cR10-KD3 active at 1µM; cTAT-KD3 active at 1-12µM; 3 cancer cell lines; direct translocation superior
How the study worked
Researchers conjugated KD3 to a panel of cyclic cell-penetrating peptides. They measured binding affinity for MDM2/MDMX, cellular uptake mechanisms (endocytosis vs translocation), p53 pathway activation, and apoptosis in three cancer cell lines. Hemolysis and toxicity to normal blood cells were also assessed.
Who was studied
MCF7, A549, HCT116 cancer cell lines (in vitro)
What this study cannot tell us
All testing was in cancer cell lines, not animals or humans. The study did not test whether angler peptides shrink tumors in vivo. Stability in blood and pharmacokinetics were not assessed. The hemolysis data were favorable, but full toxicity profiling in animals is needed.
Read the original research
Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
ACS chemical biology, 16(2), 414-428
Citation
Philippe, Grégoire J-B; Mittermeier, Anna; Lawrence, Nicole; Huang, Yen-Hua; Condon, Nicholas D; Loewer, Alexander; Craik, David J; Henriques, Sónia T. (2021). Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.. ACS chemical biology, 16(2), 414-428. https://doi.org/10.1021/acschembio.0c00988